Public Law 114–146: To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.Public Law146Public Law 114–146130 Stat. 3572016-04-192016-04-19United States Government Publishing OfficeNational Archives and Records AdministrationOffice of the Federal Registertext/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.GPO Locator to USLM Converter 4.15.31;Stage2.202507022026-01-03114publicPUBLIC LAW 114–146—APR. 19, 2016130 STAT. 357Public Law114–146114th CongressAn ActTo expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.
Apr. 19, 2016
[S. 2512]
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
Adding Zika Virus to the FDA Priority Review Voucher Program Act.
SECTION 1.
21 USC 301 note.
SHORT TITLE. This Act may be cited as the “Adding Zika Virus to the FDA Priority Review Voucher Program Act”.SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER PROGRAM TO ENCOURAGE TREATMENTS FOR ZIKA VIRUS DISEASE. Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—(1) by redesignating subparagraph (R) as subparagraph (S);(2) in subparagraph (Q), by striking “Filoviruses” and inserting “Filovirus Diseases”; and(3) by inserting after subparagraph (Q) the following:“(R) Zika Virus Disease.”.ApprovedApril 19, 2016.LEGISLATIVE HISTORY—S. 2512:CONGRESSIONAL RECORD, Vol. 162 (2016):